Cognition Therapeutics
CGTX

$0.6094

1.72%

Market Cap: $24.5M

About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Employees: 25

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

75% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 8

2% less funds holding

Funds holding: 47 [Q1] → 46 (-1) [Q2]

4.93% less ownership

Funds ownership: 18.19% [Q1] → 13.26% (-4.93%) [Q2]

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

32% less capital invested

Capital invested by funds: $12.9M [Q1] → $8.82M (-$4.09M) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$1

64%

upside

Avg. target

$6.75

1,008%

upside

High target

$14

2,197%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 121 / 273 met price target	720%upside $5	Buy Maintained	12 Aug 2024
B. Riley Securities Mayank Mamtani 58% 1-year accuracy 15 / 26 met price target	64%upside $1	Neutral Downgraded	6 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 121 / 273 met price target	1,049%upside $7	Buy Maintained	1 Aug 2024
Rodman & Renshaw Elemer Piros 50% 1-year accuracy 3 / 6 met price target	2,197%upside $14	Buy Reiterated	2 Jul 2024

See Analyst Rankings

Financial journalist opinion

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company's president and CEO, Lisa Ricciardi will participate in two investor conferences in September.

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that results from the SEQUEL study of CT1812, the Company's lead candidate for the treatment of Alzheimer's disease, were published in The Journal of Prevention of Alzheimer's Disease . SEQUEL was a single-site study that measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer's disease following 29-days of treatment with CT1812 or placebo. In this study, CT1812-treated participants exhibited consistent trends of improvement across all prespecified electroencephalography (EEG) parameters with several reaching significance, including the change in relative theta power in the central region (p=0.006) of the brain and AEC-c* (p=0.034), which assesses the connectivity between brain regions.

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript

Cognition Therapeutics, Inc. (NASDAQ:CGTX ) Q2 2024 Earnings Conference Call August 11, 2024 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, LLC Lisa Ricciardi - Chief Executive Officer John Doyle - Chief Financial Officer Anthony Caggiano - Chief Medical Officer, Head of R&D Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Daniil Gataulin - Chardan Operator Hello, and thank you for standing by.

Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

- Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures -

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

- Conference Call and Live Audio Webcast Scheduled for August 8, 2024 - - Conference Call and Live Audio Webcast Scheduled for August 8, 2024 -

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?

Cognition Therapeutics (NASDAQ: CGTX ) stock is falling hard on Monday after the clinical-stage biopharmaceutical company provided results from its proof-of-concept Phase 2 ‘SHINE' study. This study evaluated the effectiveness of treating patients with CT1812.

Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?

Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer's disease

Cognition Therapeutics Inc. CGTX, +12.86% on Monday announced positive results from a Phase 2 trial of an oral treatment for mild-to-moderate Alzheimer's disease that showed 40% mean improvement in cognitive measures compared with placebo. The Purchase, N.Y.

Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer's disease

Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients

- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo - - Consistent Positive Changes Across Cognitive and Functional Measures - - Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate - - Significant Changes in Neurofilament Light Chain, a Marker of Neurodegeneration - - Investor Webcast to be Conducted at 8:30a.m. ET to Review Findings -

Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024

PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024 at 8:30a.m. ET to discuss the clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study. SHINE enrolled 153 adults with mild-to-moderate Alzheimer's disease who were randomized to receive once-daily oral doses of CT1812 (100mg or 300mg) or placebo for six months. The only way to participate in the live webcast is to register online by clicking here. The event will also be archived on the Investor Relations section of the Cognition website.

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024

Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, 2024.

Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

See News Rankings